Search Result
Results for "
signature
" in MedChemExpress (MCE) Product Catalog:
4
Isotope-Labeled Compounds
| Cat. No. |
Product Name |
Target |
Research Areas |
Chemical Structure |
-
- HY-126855
-
|
7-Sulfocholic acid
|
G protein-coupled Bile Acid Receptor 1
MHC
|
Metabolic Disease
|
|
Cholic acid 7-sulfate (7-Sulfocholic acid) is a selective agonist targeting TGR5 (EC50=0.17 μM) and a ligand for MHC class I-related protein (MR1). As a gut-restricted TGR5 agonist, cholic acid 7-sulfate binds to TGR5 on enteroendocrine L cells, induces GLP-1 secretion, and improves glucose tolerance in a TGR5-dependent manner. Cholic acid 7-sulfate also acts as an endogenous ligand for MR1, promoting the survival of mucosal-associated invariant T cells MAIT and the expression of homeostatic gene signatures, affecting MAIT cell development and function. Cholic acid 7-sulfate is mainly used in the research of diabetes and MAIT cell-related immune regulation .
|
-
-
- HY-138280
-
DTHIB
Maximum Cited Publications
6 Publications Verification
|
HSP
|
Cancer
|
|
DTHIB is a direct and selective heat shock factor 1 (HSF1) inhibitor with a Kd of 160 nM for DTHIB binding to the HSF1 DNA binding domain (DBD). DTHIB inhibits HSF1 cancer gene signature (HSF1 CaSig) and selectively stimulates degradation of nuclear HSF1. DTHIB has potently anticancer activities and can be used for prostate cancer research .
|
-
-
- HY-137438
-
|
TG-1701
|
Btk
|
Cancer
|
|
Edralbrutinib (TG-1701) is a highly selective, orally available irreversible BTK inhibitor, with an EC50 of 6.70 nM and a Kd of 3 nM against human BTK. Edralbrutinib inhibits downstream signaling of the B cell receptor, induces dephosphorylation of Ikaros Ser442/445, promotes nuclear exclusion of Ikaros, attenuates Ikaros gene signatures, and exerts anti-tumor activity. Edralbrutinib can be used in research related to B-cell non-Hodgkin lymphoma, chronic lymphocytic leukemia, mantle cell lymphoma, follicular lymphoma, and diffuse large B-cell lymphoma .
|
-
-
- HY-P99459
-
|
BG 9924; TT-47
|
TNF Receptor
CXCR
|
Inflammation/Immunology
|
Baminercept (BG 9924; TT-47) is an Ig fusion protein targeting the lymphotoxin β receptor (LTβR). Baminercept effectively regulates subsets of circulating immune cells by inhibiting LIGHT, LT-α1β2 and their receptors. Baminercept also increases blood lymphocyte counts and reduces plasma CXCL13 levels. Baminercept carries a high risk of hepatotoxicity. Baminercept can be used in research on rheumatoid arthritis and primary Sjögren's syndrome .
|
-
-
- HY-15241
-
|
LCQ-195; AT9311
|
CDK
|
Cancer
|
|
NVP-LCQ195 (LCQ-195) is an inhibitor of CDK1/2/3/5/9. NVP-LCQ195 induces cell cycle arrest and eventual apoptotic cell death of multiple myeloma (MM) cells. NVP-LCQ195 triggers decreased amplitude of transcriptional signatures related to oncogenesis, drug resistance and stem cell renewal in MM cell lines .
|
-
-
- HY-139621
-
|
|
DNA Alkylator/Crosslinker
|
Cancer
|
|
Colibactin 742 is a covalently binding DNA-damaging agent targeting DNA, with an IC50 of 5.2 μM against human cervical cancer cells (HeLa). Colibactin 742 covalently binds to DNA, forming interstrand crosslinks (ICLs), activating the Fanconi anemia DNA repair pathway, inducing γH2AX and FANCD2 foci formation and cell cycle arrest, while exacerbating mismatch repair deficiency (MMRd)-related mutations. Colibactin 742 can mimic the genotoxicity of natural Colibactin while avoiding its instability, and is mainly used in colorectal cancer (CRC) related research, including microbial tumorigenesis mechanisms, DNA damage repair pathways, and mutation signature analysis .
|
-
-
- HY-123820
-
|
|
mGluR
|
Neurological Disease
|
|
LY3020371 hydrochloride is a potent, selective metabotropic glutamate 2/3 receptor (mGlu2/3) antagonist with Ki of 5.3 and 2.5 nM, potently blocks cAMP formation with IC50 of 16.2 nM . LY3020371 hydrochloride exerts an antidepressant-like signature in vivo .
|
-
-
- HY-P3146A
-
|
|
Drug Metabolite
|
Cancer
|
|
FTISADTSK acetate is an endogenous stable signature peptide from Trastuzumab monitored by selected reaction monitoring (SRM) .
|
-
-
- HY-P3146S
-
|
|
Isotope-Labeled Compounds
|
Cancer
|
|
FTISADTSK- 13C6, 15N2 TFA is 13C- and 15N-labeled FTISADTSK (HY-P3146). FTISADTSK is an endogenous stable signature peptide from Trastuzumab monitored by selected reaction monitoring (SRM) .
|
-
-
- HY-146052
-
|
|
Atg8/LC3
Autophagy
|
Cancer
|
|
Autophagy inducer 3 has autophagy induced activity. Autophagy inducer 3 possesses robust autophagic cell death in diverse cancer cells sparing normal counterpart. Autophagy inducer 3 induces lethal autophagy by formation of characteristic autophagic vacuoles, LC3 puncta formation, upregulation of signature autophagy markers like Beclin and Atg family proteins .
|
-
-
- HY-P3147A
-
|
|
Drug Metabolite
|
Others
|
|
IYPTNGYTR acetate, a deamidation-sensitive signature peptide, is a deamidation product of Trastuzumab. IYPTNGYTR acetate can be used to monitor in vivo Trastuzumab metabolism .
|
-
-
- HY-P3146
-
|
|
Drug Metabolite
|
Cancer
|
|
FTISADTSK is an endogenous stable signature peptide from Trastuzumab monitored by selected reaction monitoring (SRM) .
|
-
-
- HY-P5168S
-
|
|
Isotope-Labeled Compounds
SARS-CoV
|
Infection
|
|
GPSVFPLAPSSK- 13C6, 15N2 is the 13C- and 15N-labeled GPSVFPLAPSSK. GPSVFPLAPSSK is an IgG1 signature peptide of anti-SARS-CoV-2 antibodies. GPSVFPLAPSSK can be used for the quantification of the specific isolation of anti-SARS-CoV-2 antibodies .
|
-
-
- HY-P3147
-
|
|
Drug Metabolite
|
Others
|
|
IYPTNGYTR, a deamidation-sensitive signature peptide, is a deamidation product of Trastuzumab. IYPTNGYTR can be used to monitor in vivo Trastuzumab metabolism .
|
-
-
- HY-P5168AS
-
|
|
Isotope-Labeled Compounds
SARS-CoV
|
Infection
|
|
GPSVFPLAPSSK- 13C6, 15N2 TFA is the 13C- and 15N-labeled GPSVFPLAPSSK. GPSVFPLAPSSK is an IgG1 signature peptide of anti-SARS-CoV-2 antibodies. GPSVFPLAPSSK can be used for the quantification of the specific isolation of anti-SARS-CoV-2 antibodies .
|
-
-
- HY-162910
-
|
|
Xanthine Oxidase
HDAC
Autophagy
Apoptosis
|
Metabolic Disease
Inflammation/Immunology
Cancer
|
|
HDAC-IN-79 (compound 4) is an orally active dual xanthine oxidase-HDAC inhibitor (Xanthine oxidase: IC50=6.6 nM; HDAC1: IC50=134 nM; HDAC2: IC50=284 nM; HDAC3: IC50=173 nM; HDAC6: IC50=1.32 nM;), with significant in vivo anti-hyperuricemia and anti-tumor activities. HDAC-IN-79 is the most potent cell growth inhibitor (IC50=0.706 μM) of leukemia HL60 cells, induces apoptosis and autophagy, and can regulate the expression levels of signature biomarkers associated with intracellular HDAC inhibition .
|
-
-
- HY-126855S
-
|
7-Sulfocholic acid-d4
|
Isotope-Labeled Compounds
G protein-coupled Bile Acid Receptor 1
MHC
|
Metabolic Disease
|
|
Cholic acid 7-sulfate-d4 (7-Sulfocholic acid-d4) is the deuterium labeled Cholic acid 7-sulfate (HY-126855). Cholic acid 7-sulfate is a selective agonist targeting TGR5 (EC50=0.17 μM) and a ligand for MHC class I-related protein (MR1). As a gut-restricted TGR5 agonist, cholic acid 7-sulfate binds to TGR5 on enteroendocrine L cells, induces GLP-1 secretion, and improves glucose tolerance in a TGR5-dependent manner. Cholic acid 7-sulfate also acts as an endogenous ligand for MR1, promoting the survival of mucosal-associated invariant T cells MAIT and the expression of homeostatic gene signatures, affecting MAIT cell development and function. Cholic acid 7-sulfate is mainly used in the research of diabetes and MAIT cell-related immune regulation .
|
-
-
- HY-15313B
-
|
|
Histone Demethylase
|
Metabolic Disease
Cancer
|
|
CBB1007 hydrochloride is a reversible and selective LSD1 inhibitor with an IC50 of 5.27 µM for human LSD1. CBB1007 hydrochloride significantly blocks the demethylase activity of LSD1 on H3K4Me2 and H3K4Me. CBB1007 hydrochloride shows selectivity for LSD1 over LSD2 or JARID1A, and induces differentiation-related genes in pluripotent cells. CBB1007 hydrochloride is studied in non-pluripotent cancer research, targeting teratocarcinoma, embryonic carcinoma, and seminoma .
|
-
-
- HY-P11556
-
|
|
Biochemical Assay Reagents
|
Others
|
|
LR-13 is a signature peptide identified from the egg white allergen ovalbumin (OVA). LR-13 can be used as a marker peptide for the detection of OVA allergens using UHPLC-MS/MS .
|
-
-
- HY-P11575
-
|
|
Biochemical Assay Reagents
|
Others
|
|
LSFNPTQLEEQCHI is a signature peptide that can be isolated from β-lactoglobulin in cow milk. LSFNPTQLEEQCHI can be used as a maker peptide in a proteomics-based method for quantifying the percentage of cow milk in raw materials for dairy products .
|
-
-
- HY-180590
-
|
|
Nucleoside Antimetabolite/Analog
|
Cardiovascular Disease
|
|
3α,7α,12α,26-Tetrahydroxy-5β-cholestane is an important key metabolic signature of Quercetin (HY-18085) in primary bile acid biosynthesis. 3α,7α,12α,26-Tetrahydroxy-5β-cholestane can be used for the study of atherosclerosis .
|
-
-
- HY-P992454
-
|
|
Tim3
|
Cancer
|
|
S095018 (Sym023) is a human IgG2-type inhibitor targeting T cell immunoglobulin and TIM-3. S095018 competitively blocks the binding of multiple ligands such as Gal-9 and phosphatidylserine to TIM-3. S095018 stimulates the anti-tumor activity of T cells, dendritic cells and macrophages, and exhibits good safety both as a monotherapy and in combination with the anti-PD-1 antibody Sym021. S095018 also induces an increase in the density of CD8 + T cells in the tumor microenvironment, and upregulates gene signatures associated with IFN-γ signaling, antigen presentation and T cell activation. S095018 can be used for the research of advanced/metastatic recurrent biliary tract cancer .
|
-
-
- HY-P992394
-
|
CNTO-6358
|
IFNAR
|
Inflammation/Immunology
|
|
JNJ-55920839 (CNTO-6358) is a fully human immunoglobulin G1κ monoclonal antibody and a selective Interferon α/ω neutralizer, with a Kd value of 0.9-10.7 pM against hIFNα and a Kd of 1.44 pM against IFNω. JNJ-55920839 can be used in research related to systemic lupus erythematosus .
|
-
-
- HY-180331
-
|
|
MDM-2/p53
|
Cancer
|
|
NVP-CFC218 is a selective TP53-MDM2 inhibitor with a structure and biochemical profile similar to NVP-CGM097 (HY-15954) (IC50 of 1.6 nM: displacing the p53 peptide from the surface of HDM2). It is used to analyze pharmacological sensitivity in cell lines and is also applicable in cancer research [1] .
|
-
-
-
HY-L217
-
|
|
336 compounds
|
|
Metabolic abnormalities lead to dysfunction of metabolic pathways and the accumulation or lack of metabolites, which are recognized hallmarks of the disease. The metabolite signature is closely related to the disease phenotype and is very useful for predicting the diagnosis and prognosis of the disease as well as monitoring treatment. Metabolites can be used as disease markers for diagnostic therapy. As the classic model of disease experiment in vivo, mice metabolites also play a role in disease diagnosis and mechanism research.
MCE provides 336 mouse metabolites that can be used in disease research.
|
-
-
HY-L207
-
|
|
664 compounds
|
|
Metabolomics is the large-scale study of cellular metabolic complement, with proven utility in both basic and applied studies of plants, microorganisms, and mammals. As an important tool for the study of complex biological systems, metabolomics monitors the complex molecular networks that exist in the natural flow of information from genes to mRNA and proteins to organisms. The metabolome is composed of biomolecules that most closely resemble the phenotype of an organism, and changes in its composition can easily lead to the production of diseases. Therefore, metabolomics has received much attention in drug target discovery, drug response and translational research of disease mechanisms. Mass spectrometry-based metabolomics methods can simultaneously detect and quantify thousands of metabolite signatures, thereby characterizing the pathophysiological mechanisms of various biomedical symptoms.
MCE can provide 664 mass spectrometry human endogenous metabolites that can be used for metabolite identification and quantification, functional cell detection and phenotypic screening of mass spectrometry.
|
| Cat. No. |
Product Name |
Target |
Research Area |
-
- HY-P3146A
-
|
|
Drug Metabolite
|
Cancer
|
|
FTISADTSK acetate is an endogenous stable signature peptide from Trastuzumab monitored by selected reaction monitoring (SRM) .
|
-
- HY-P3146S
-
|
|
Isotope-Labeled Compounds
|
Cancer
|
|
FTISADTSK- 13C6, 15N2 TFA is 13C- and 15N-labeled FTISADTSK (HY-P3146). FTISADTSK is an endogenous stable signature peptide from Trastuzumab monitored by selected reaction monitoring (SRM) .
|
-
- HY-P3147A
-
|
|
Drug Metabolite
|
Others
|
|
IYPTNGYTR acetate, a deamidation-sensitive signature peptide, is a deamidation product of Trastuzumab. IYPTNGYTR acetate can be used to monitor in vivo Trastuzumab metabolism .
|
-
- HY-P3146
-
|
|
Drug Metabolite
|
Cancer
|
|
FTISADTSK is an endogenous stable signature peptide from Trastuzumab monitored by selected reaction monitoring (SRM) .
|
-
- HY-P5168S
-
|
|
Isotope-Labeled Compounds
SARS-CoV
|
Infection
|
|
GPSVFPLAPSSK- 13C6, 15N2 is the 13C- and 15N-labeled GPSVFPLAPSSK. GPSVFPLAPSSK is an IgG1 signature peptide of anti-SARS-CoV-2 antibodies. GPSVFPLAPSSK can be used for the quantification of the specific isolation of anti-SARS-CoV-2 antibodies .
|
-
- HY-P3147
-
|
|
Drug Metabolite
|
Others
|
|
IYPTNGYTR, a deamidation-sensitive signature peptide, is a deamidation product of Trastuzumab. IYPTNGYTR can be used to monitor in vivo Trastuzumab metabolism .
|
-
- HY-P5168AS
-
|
|
Isotope-Labeled Compounds
SARS-CoV
|
Infection
|
|
GPSVFPLAPSSK- 13C6, 15N2 TFA is the 13C- and 15N-labeled GPSVFPLAPSSK. GPSVFPLAPSSK is an IgG1 signature peptide of anti-SARS-CoV-2 antibodies. GPSVFPLAPSSK can be used for the quantification of the specific isolation of anti-SARS-CoV-2 antibodies .
|
-
- HY-P11556
-
|
|
Biochemical Assay Reagents
|
Others
|
|
LR-13 is a signature peptide identified from the egg white allergen ovalbumin (OVA). LR-13 can be used as a marker peptide for the detection of OVA allergens using UHPLC-MS/MS .
|
-
- HY-P11575
-
|
|
Biochemical Assay Reagents
|
Others
|
|
LSFNPTQLEEQCHI is a signature peptide that can be isolated from β-lactoglobulin in cow milk. LSFNPTQLEEQCHI can be used as a maker peptide in a proteomics-based method for quantifying the percentage of cow milk in raw materials for dairy products .
|
| Cat. No. |
Product Name |
Target |
Research Area |
Image |
-
- HY-P99459
-
|
BG 9924; TT-47
|
TNF Receptor
CXCR
|
Inflammation/Immunology
|
Baminercept (BG 9924; TT-47) is an Ig fusion protein targeting the lymphotoxin β receptor (LTβR). Baminercept effectively regulates subsets of circulating immune cells by inhibiting LIGHT, LT-α1β2 and their receptors. Baminercept also increases blood lymphocyte counts and reduces plasma CXCL13 levels. Baminercept carries a high risk of hepatotoxicity. Baminercept can be used in research on rheumatoid arthritis and primary Sjögren's syndrome .
|
-
(5)
-
- HY-P992454
-
|
|
Tim3
|
Cancer
|
|
S095018 (Sym023) is a human IgG2-type inhibitor targeting T cell immunoglobulin and TIM-3. S095018 competitively blocks the binding of multiple ligands such as Gal-9 and phosphatidylserine to TIM-3. S095018 stimulates the anti-tumor activity of T cells, dendritic cells and macrophages, and exhibits good safety both as a monotherapy and in combination with the anti-PD-1 antibody Sym021. S095018 also induces an increase in the density of CD8 + T cells in the tumor microenvironment, and upregulates gene signatures associated with IFN-γ signaling, antigen presentation and T cell activation. S095018 can be used for the research of advanced/metastatic recurrent biliary tract cancer .
|
-
(5)
-
- HY-P992394
-
|
CNTO-6358
|
IFNAR
|
Inflammation/Immunology
|
|
JNJ-55920839 (CNTO-6358) is a fully human immunoglobulin G1κ monoclonal antibody and a selective Interferon α/ω neutralizer, with a Kd value of 0.9-10.7 pM against hIFNα and a Kd of 1.44 pM against IFNω. JNJ-55920839 can be used in research related to systemic lupus erythematosus .
|
-
(5)
| Cat. No. |
Product Name |
Category |
Target |
Chemical Structure |
| Cat. No. |
Product Name |
Chemical Structure |
-
- HY-P3146S
-
|
|
|
FTISADTSK- 13C6, 15N2 TFA is 13C- and 15N-labeled FTISADTSK (HY-P3146). FTISADTSK is an endogenous stable signature peptide from Trastuzumab monitored by selected reaction monitoring (SRM) .
|
-
-
- HY-P5168S
-
|
|
|
GPSVFPLAPSSK- 13C6, 15N2 is the 13C- and 15N-labeled GPSVFPLAPSSK. GPSVFPLAPSSK is an IgG1 signature peptide of anti-SARS-CoV-2 antibodies. GPSVFPLAPSSK can be used for the quantification of the specific isolation of anti-SARS-CoV-2 antibodies .
|
-
-
- HY-P5168AS
-
|
|
|
GPSVFPLAPSSK- 13C6, 15N2 TFA is the 13C- and 15N-labeled GPSVFPLAPSSK. GPSVFPLAPSSK is an IgG1 signature peptide of anti-SARS-CoV-2 antibodies. GPSVFPLAPSSK can be used for the quantification of the specific isolation of anti-SARS-CoV-2 antibodies .
|
-
-
- HY-126855S
-
|
|
|
Cholic acid 7-sulfate-d4 (7-Sulfocholic acid-d4) is the deuterium labeled Cholic acid 7-sulfate (HY-126855). Cholic acid 7-sulfate is a selective agonist targeting TGR5 (EC50=0.17 μM) and a ligand for MHC class I-related protein (MR1). As a gut-restricted TGR5 agonist, cholic acid 7-sulfate binds to TGR5 on enteroendocrine L cells, induces GLP-1 secretion, and improves glucose tolerance in a TGR5-dependent manner. Cholic acid 7-sulfate also acts as an endogenous ligand for MR1, promoting the survival of mucosal-associated invariant T cells MAIT and the expression of homeostatic gene signatures, affecting MAIT cell development and function. Cholic acid 7-sulfate is mainly used in the research of diabetes and MAIT cell-related immune regulation .
|
-
Your information is safe with us. * Required Fields.
Inquiry Information
- Product Name:
- Cat. No.:
- Quantity:
- MCE Japan Authorized Agent:
